Cargando…

Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial

BACKGROUND: Oral cholera vaccine (OCV) is a feasible tool to prevent or mitigate cholera outbreaks. A better understanding of the vaccine’s efficacy among different age groups and how rapidly its protection wanes could help guide vaccination policy. METHODS: To estimate the level and duration of OCV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fong, Youyi, Halloran, M. Elizabeth, Park, Jin Kyung, Marks, Florian, Clemens, John D., Chao, Dennis L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819652/ https://www.ncbi.nlm.nih.gov/pubmed/29463233 http://dx.doi.org/10.1186/s12879-018-2981-4

Ejemplares similares

A Randomized, Placebo-Controlled Trial of the Bivalent Killed, Whole-Cell, Oral Cholera Vaccine in Adults and Children in a Cholera Endemic Area in Kolkata, India
por: Mahalanabis, Dilip, et al.
Publicado: (2008)

Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh
por: Chowdhury, Fahima, et al.
Publicado: (2020)

Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines
por: Capeding, Maria Rosario Z., et al.
Publicado: (2017)

Vibriocidal Antibody Responses to a Bivalent Killed Whole-Cell Oral Cholera Vaccine in a Phase III Trial in Kolkata, India
por: Kanungo, Suman, et al.
Publicado: (2014)

Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial
por: Ali, Mohammad, et al.
Publicado: (2021)

Immunogenicity of a Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine, Shanchol, in Haiti
por: Charles, Richelle C., et al.
Publicado: (2014)

A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia
por: Desai, Sachin N., et al.
Publicado: (2015)

Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial
por: Khan, Ashraful Islam, et al.
Publicado: (2019)

Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model
por: Lee, Eun Young, et al.
Publicado: (2018)

Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India
por: Raghava Mohan, Venkata, et al.
Publicado: (2019)

Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study
por: Franke, Molly F, et al.
Publicado: (2018)

An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India
por: Kanungo, Suman, et al.
Publicado: (2015)

A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines()
por: Russo, Paola, et al.
Publicado: (2018)

Assessing Vaccine Herd Protection by Killed Whole-Cell Oral Cholera Vaccines Using Different Study Designs
por: Ali, Mohammad, et al.
Publicado: (2019)

Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis
por: Bi, Qifang, et al.
Publicado: (2017)

Safety of the Recombinant Cholera Toxin B Subunit, Killed Whole-Cell (rBS-WC) Oral Cholera Vaccine in Pregnancy
por: Hashim, Ramadhan, et al.
Publicado: (2012)

Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh
por: Kaisar, M. Hasanul, et al.
Publicado: (2023)

Unmasking herd protection by an oral cholera vaccine in a cluster-randomized trial
por: Ali, Mohammad, et al.
Publicado: (2019)

Asthma still kills: little change over five decades
por: Levy, Mark L
Publicado: (2014)

622. Increased IgA Coating of Gut Microbes After Administration of Killed, Whole-Cell Oral Cholera Vaccine
por: Weil, Ana, et al.
Publicado: (2018)

Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysaccharide antigen in Haitian adults
por: Falkard, Brie, et al.
Publicado: (2019)

Gut Microbiota and Development of Vibrio cholerae-Specific Long-Term Memory B Cells in Adults after Whole-Cell Killed Oral Cholera Vaccine
por: Chac, Denise, et al.
Publicado: (2021)

Use of oral cholera vaccine as a vaccine probe to define the geographical dimensions of person-to-person transmission of cholera
por: Ali, Mohammad, et al.
Publicado: (2018)

Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera
por: Im, Justin, et al.
Publicado: (2019)

Can cholera ‘hotspots’ be converted to cholera ‘coldspots’ in cholera endemic countries? The Matlab, Bangladesh experience
por: Zaman, K., et al.
Publicado: (2020)

The interplay between WASH practices and vaccination with oral cholera vaccines in protecting against cholera in urban Bangladesh: Reanalysis of a cluster-randomized trial
por: Chowdhury, Fahima, et al.
Publicado: (2023)

Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults
por: Matias, Wilfredo R., et al.
Publicado: (2016)

Re-evaluating herd protection by Vi typhoid vaccine in a cluster randomized trial
por: Ali, Mohammad, et al.
Publicado: (2019)

Cholera ante portas – The re-emergence of cholera in Kinshasa after a ten-year hiatus
por: Bompangue, Didier, et al.
Publicado: (2012)

An orienting response is not enough: Bivalency not infrequency causes the bivalency effect
por: Rey-Mermet, Alodie, et al.
Publicado: (2013)

Re-emergence of cholera outbreak in DRC: A silent fight
por: Aborode, Abdullahi Tunde, et al.
Publicado: (2023)

Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139
por: Kamruzzaman, Mohammad, et al.
Publicado: (2021)

Evaluation of antibody responses to outer membrane vesicles (OMVs) and killed whole cell of Vibrio cholerae O1 El Tor in immunized mice
por: Sedaghat, Manijeh, et al.
Publicado: (2019)

Five Years of Cholera Prevalence in the Turkish Empire
por: Clemow, Frank G.
Publicado: (1904)

Comparative Effectiveness of Different Strategies of Oral Cholera Vaccination in Bangladesh: A Modeling Study
por: Dimitrov, Dobromir T., et al.
Publicado: (2014)

Glucose confers protection to Escherichia coli against contact killing by Vibrio cholerae
por: Crisan, Cristian V., et al.
Publicado: (2021)

A five-year study on the epidemiological approaches to cholera in Iran
por: Mafi, Moharam, et al.
Publicado: (2016)

Potential for Controlling Cholera Using a Ring Vaccination Strategy: Re-analysis of Data from a Cluster-Randomized Clinical Trial
por: Ali, Mohammad, et al.
Publicado: (2016)

A shared vision for macromolecular crystallography over the next five years
por: Förster, Andreas, et al.
Publicado: (2019)

Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh
por: Akter, Aklima, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ukie3duvaeubl7rkdkso3vp6on